论文部分内容阅读
近30年来,我国急性心肌梗死(acute myocardial infarction,AMI)血运重建迅速普及,药物干预更加规范化,但血运重建后仍有25%~35%的AMI患者不能获得心肌组织的灌注,AMI仍是心血管病的主要死亡原因之一。活血化瘀中药具有促进心肌毛细血管再生、抗栓、抗炎、改善心室重构等作用。结合西医常规治疗可进一步降低AMI住院并发症和死亡的发生率。但是,AMI是一个全身代谢性疾病,其涉及的病理生理变化远非影像学显示的局部狭窄程度和斑块大小所能解释。如何将强化降脂、抗血小板的不良反应和风险效益比,如何发挥结合医学优势并将其转化应用于AMI临床应用,皆须今后逐步明确。
In the recent 30 years, the revascularization of acute myocardial infarction (AMI) in China has been rapidly popularized and the drug intervention is more standardized. However, 25% to 35% of AMI patients after revascularization are still unable to obtain myocardial perfusion. AMI One of the major causes of death from cardiovascular disease. Blood circulation Chinese medicine has to promote myocardial regeneration, antithrombotic, anti-inflammatory, improve ventricular remodeling and other effects. Combined with Western conventional treatment can further reduce the incidence of AMI hospital complications and deaths. However, AMI is a systemic metabolic disease and its pathophysiological changes are far beyond the limits of local stenosis and plaque size that imaging can explain. How to strengthen the lipid-lowering, anti-platelet adverse reactions and risk-benefit ratio, how to play a combination of medical advantages and its application in the clinical application of AMI must be gradually clear in the future.